Cancer immunotherapy comes of age.

Details

Serval ID
serval:BIB_52B4845E4E87
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Cancer immunotherapy comes of age.
Journal
Nature
Author(s)
Mellman I., Coukos G., Dranoff G.
ISSN
1476-4687 (Electronic)
ISSN-L
0028-0836
Publication state
Published
Issued date
2011
Volume
480
Number
7378
Pages
480-489
Language
english
Notes
Publication types: Journal Article ; ReviewPublication Status: epublish
Abstract
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
Keywords
Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents/therapeutic use, Cancer Vaccines/therapeutic use, Humans, Immunologic Factors/therapeutic use, Immunotherapy, Male, Neoplasms/drug therapy, Neoplasms/therapy, Prostatic Neoplasms/therapy, T-Lymphocytes/immunology
Pubmed
Web of science
Create date
14/10/2014 11:43
Last modification date
20/08/2019 14:08
Usage data